Market Overview

Ligand Pharma Begins Pivotal Trial of Captisol-Enabled Propylene Glycol-Free Melphalan for Multiple Myeloma Patients

Related LGND
UPDATE: Avion Pharma Reports Signing of Commercial License Deal with Ligand Pharma for Development, Commercialization of Four Captisol-Enabled Programs, Ligand Entitled to Upfront Payment
Stocks To Watch For August 12, 2014

Ligand Pharma (NASDAQ: LGND) announced today that it has initiated a pivotal trial of Captisol-enabled^®, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma. This multi-center trial will evaluate safety and efficacy in 60 patients, and is intended to confirm the results from an earlier Phase 2 study demonstrating that the PG-free melphalan intravenous formulation was safe and well-tolerated, and met the requirements for establishment of bioequivalence to the current commercial intravenous formulation of melphalan (sold by GlaxoSmithKline as Alkeran^® for Injection).

Given the robust dataset compiled to date along with the pivotal study design, Ligand believes that should this pivotal trial produce positive results, the Company will be in a position to submit a 505(b)(2) New Drug Application to the U.S. Food and Drug Administration.

Posted-In: News FDA

 

Related Articles (LGND)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters